• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长期非进展和广泛的 HIV-1 特异性增殖性 T 细胞应答。

Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses.

机构信息

Department of Medicine, Imperial College London London, UK.

出版信息

Front Immunol. 2013 Mar 1;4:58. doi: 10.3389/fimmu.2013.00058. eCollection 2013.

DOI:10.3389/fimmu.2013.00058
PMID:23459797
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3585435/
Abstract

Complex mechanisms underlying the maintenance of fully functional, proliferative, HIV-1-specific T-cell responses involve processes from early T-cell development through to the final stages of T-cell differentiation and antigen recognition. Virus-specific proliferative CD4 and CD8 T-cell responses, important for the control of infection, are observed in some HIV-1(+) patients during early stages of disease, and are maintained in long-term non-progressing subjects. In the vast majority of HIV-1(+) patients, full immune functionality is lost when proliferative HIV-1-specific T-cell responses undergo a variable progressive decline throughout the course of chronic infection. This appears irreparable despite administration of potent combination antiretroviral therapy, which to date is non-curative, necessitating life-long administration and the development of effective, novel, therapeutic interventions. While a sterilizing cure, involving clearance of virus from the host, remains a primary aim, a "functional cure" may be a more feasible goal with considerable impact on worldwide HIV-1 infection. Such an approach would enable long-term co-existence of host and virus in the absence of toxic and costly drugs. Effective immune homeostasis coupled with a balanced response appropriately targeting conserved viral antigens, in a manner that avoids hyperactivation and exhaustion, may prove to be the strongest correlate of durable viral control. This review describes novel concepts underlying full immune functionality in the context of HIV-1 infection, which may be utilized in future strategies designed to improve upon existing therapy. The aim will be to induce long-term non-progressor or elite controller status in every infected host, through immune-mediated control of viremia and reduction of viral reservoirs, leading to lower HIV-1 transmission rates.

摘要

维持具有完全功能、增殖性、HIV-1 特异性 T 细胞反应的复杂机制涉及从早期 T 细胞发育到 T 细胞分化和抗原识别的最后阶段的过程。在疾病的早期阶段,一些 HIV-1(+)患者中观察到病毒特异性增殖性 CD4 和 CD8 T 细胞反应,这对于控制感染很重要,并且在长期非进展性受试者中得到维持。在绝大多数 HIV-1(+)患者中,当增殖性 HIV-1 特异性 T 细胞反应在慢性感染过程中发生可变的进行性下降时,完全的免疫功能丧失。尽管给予了强效的联合抗逆转录病毒治疗,但这种情况似乎是不可挽回的,因为到目前为止,这种治疗方法并不能治愈疾病,需要终身给药,并需要开发有效的新型治疗干预措施。虽然清除宿主病毒的“根治性治愈”仍然是主要目标,但“功能性治愈”可能是一个更可行的目标,对全球 HIV-1 感染具有重大影响。这种方法将使宿主和病毒在没有毒性和昂贵药物的情况下长期共存。有效的免疫稳态加上适当靶向保守病毒抗原的平衡反应,以避免过度激活和衰竭,可能被证明是持久病毒控制的最强相关因素。本文综述了 HIV-1 感染背景下完全免疫功能的新概念,这些概念可能用于未来旨在改善现有治疗方法的策略中。目标是通过免疫介导的病毒血症控制和减少病毒库,在每个感染宿主中诱导长期非进展或精英控制者状态,从而降低 HIV-1 传播率。

相似文献

1
Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses.长期非进展和广泛的 HIV-1 特异性增殖性 T 细胞应答。
Front Immunol. 2013 Mar 1;4:58. doi: 10.3389/fimmu.2013.00058. eCollection 2013.
2
Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection.HIV不进展的机制;对p24抗原的强大且持续的CD4+ T细胞增殖反应与长期输血获得性HIV-1感染后病毒血症的控制及疾病不进展相关。
Retrovirology. 2008 Dec 11;5:112. doi: 10.1186/1742-4690-5-112.
3
Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness.针对人类免疫缺陷病毒、丙型肝炎病毒和巨细胞病毒的CD8 + T细胞比较揭示了在频率、免疫显性、表型和白细胞介素-2反应性方面的差异。
J Virol. 2009 Mar;83(6):2728-42. doi: 10.1128/JVI.02128-08. Epub 2009 Jan 7.
4
Two Distinct Mechanisms Leading to Loss of Virological Control in the Rare Group of Antiretroviral Therapy-Naive, Transiently Aviremic Children Living with HIV.两种不同的机制导致少数接受抗逆转录病毒治疗初治、一过性病毒血症抑制的 HIV 儿童出现病毒学控制失败。
J Virol. 2022 Jan 26;96(2):e0153521. doi: 10.1128/JVI.01535-21. Epub 2021 Nov 10.
5
Immune Control of HIV.HIV的免疫控制
J Life Sci (Westlake Village). 2019 Jun;1(1):4-37.
6
Immune responses and reconstitution in HIV-1 infected individuals: impact of anti-retroviral therapy, cytokines and therapeutic vaccination.HIV-1感染个体的免疫反应与免疫重建:抗逆转录病毒疗法、细胞因子及治疗性疫苗接种的影响
Immunol Lett. 2001 Nov 1;79(1-2):63-76. doi: 10.1016/s0165-2478(01)00267-x.
7
Mechanisms of loss of HIV-1-specific T-cell responses.HIV-1特异性T细胞反应丧失的机制。
J HIV Ther. 2002 May;7(2):30-4.
8
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.HIV-1储存库:在抗病毒免疫反应和抗逆转录病毒疗法存在的情况下病毒持续存在的机制
Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665.
9
Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells.在原发性HIV-1感染时开始的长期抗逆转录病毒治疗会影响HIV-1感染的CD4 T细胞储存库的大小、组成和衰减动力学。
J Virol. 2014 Sep 1;88(17):10056-65. doi: 10.1128/JVI.01046-14. Epub 2014 Jun 25.
10
CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles.CD8 + T细胞广度和体外病毒抑制能力可区分有无保护性HLA I类等位基因的病毒血症控制者。
J Virol. 2016 Jul 11;90(15):6818-6831. doi: 10.1128/JVI.00276-16. Print 2016 Aug 1.

引用本文的文献

1
TCellSI: A novel method for T cell state assessment and its applications in immune environment prediction.TCellSI:一种用于T细胞状态评估的新方法及其在免疫环境预测中的应用。
Imeta. 2024 Aug 26;3(5):e231. doi: 10.1002/imt2.231. eCollection 2024 Oct.
2
CBX7 is Dualistic in Cancer Progression Based on its Function and Molecular Interactions.基于其功能和分子相互作用,CBX7在癌症进展中具有双重性。
Front Genet. 2021 Oct 1;12:740794. doi: 10.3389/fgene.2021.740794. eCollection 2021.
3
Gut germinal center regeneration and enhanced antiviral immunity by mesenchymal stem/stromal cells in SIV infection.

本文引用的文献

1
Pathways of antigen processing.抗原加工途径。
Annu Rev Immunol. 2013;31:443-73. doi: 10.1146/annurev-immunol-032712-095910. Epub 2013 Jan 3.
2
High-dimensional immunomonitoring models of HIV-1-specific CD8 T-cell responses accurately identify subjects achieving spontaneous viral control.高维免疫监测模型可准确识别实现自发性病毒控制的 HIV-1 特异性 CD8 T 细胞反应。
Blood. 2013 Jan 31;121(5):801-11. doi: 10.1182/blood-2012-06-436295. Epub 2012 Dec 11.
3
HIV and HLA class I: an evolving relationship.HIV 与 HLA Ⅰ类分子:不断变化的关系。
间质干细胞/基质细胞促进 SIV 感染后肠道生发中心再生和增强抗病毒免疫。
JCI Insight. 2021 Jun 22;6(12):149033. doi: 10.1172/jci.insight.149033.
4
Insight in miRNome of Long-Term Non-Progressors and Elite Controllers Exposes Potential RNAi Role in Restraining HIV-1 Infection.对长期无进展者和精英控制者的微小RNA组的深入了解揭示了RNA干扰在抑制HIV-1感染中的潜在作用。
J Clin Med. 2020 Jul 31;9(8):2452. doi: 10.3390/jcm9082452.
5
Quantification of Viral RNA and DNA Positive Cells in Tissues From Simian Immunodeficiency Virus/Simian Human Immunodeficiency Virus Infected Controller and Progressor Rhesus Macaques.感染猿猴免疫缺陷病毒/猿猴-人类免疫缺陷病毒的控制组和进展期恒河猴组织中病毒RNA和DNA阳性细胞的定量分析
Front Microbiol. 2019 Dec 20;10:2933. doi: 10.3389/fmicb.2019.02933. eCollection 2019.
6
Subclinical cardiovascular disease in HIV controller and long-term nonprogressor populations.HIV 感染者中的亚临床心血管疾病和长期非进展者人群。
HIV Med. 2020 Apr;21(4):217-227. doi: 10.1111/hiv.12820. Epub 2019 Nov 14.
7
An integrative genomic analysis of transcriptional profiles identifies characteristic genes and patterns in HIV-infected long-term non-progressors and elite controllers.整合基因组转录谱分析鉴定了 HIV 感染的长期非进展者和精英控制者的特征基因和模式。
J Transl Med. 2019 Jan 21;17(1):35. doi: 10.1186/s12967-019-1777-7.
8
Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status.针对特定人类免疫缺陷病毒 gp41 表位的中和抗体与长期非进展者状态相关。
EBioMedicine. 2017 Aug;22:122-132. doi: 10.1016/j.ebiom.2017.07.007. Epub 2017 Jul 11.
9
Enrichment of HLA Types and Single-Nucleotide Polymorphism Associated With Non-progression in a Strictly Defined Cohort of HIV-1 Controllers.在严格定义的HIV-1控制者队列中与病情无进展相关的HLA类型和单核苷酸多态性富集情况
Front Immunol. 2017 Jun 27;8:746. doi: 10.3389/fimmu.2017.00746. eCollection 2017.
10
Multifarious immunotherapeutic approaches to cure HIV-1 infection.多种用于治愈HIV-1感染的免疫治疗方法。
Hum Vaccin Immunother. 2015;11(9):2287-93. doi: 10.1080/21645515.2015.1021523.
Immunity. 2012 Sep 21;37(3):426-40. doi: 10.1016/j.immuni.2012.09.005.
4
Redefining the viral reservoirs that prevent HIV-1 eradication.重新定义阻止 HIV-1 根除的病毒储存库。
Immunity. 2012 Sep 21;37(3):377-88. doi: 10.1016/j.immuni.2012.08.010.
5
Disease Progression in HIV-1-Infected Viremic Controllers.HIV-1 感染者病毒血症中的疾病进展。
J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):407-16. doi: 10.1097/QAI.0b013e318269c414.
6
Identification of HIV-1-specific regulatory T-cells using HLA class II tetramers.使用 HLA Ⅱ类四聚体鉴定 HIV-1 特异性调节性 T 细胞。
AIDS. 2012 Oct 23;26(16):2112-5. doi: 10.1097/QAD.0b013e328358cc75.
7
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.伏立诺他治疗可打破抗逆转录病毒治疗患者的 HIV-1 潜伏。
Nature. 2012 Jul 25;487(7408):482-5. doi: 10.1038/nature11286.
8
Towards an HIV cure: a global scientific strategy.迈向艾滋病治愈:全球科学策略。
Nat Rev Immunol. 2012 Jul 20;12(8):607-14. doi: 10.1038/nri3262.
9
From single cells to deep phenotypes in cancer.从单细胞到癌症的深度表型。
Nat Biotechnol. 2012 Jul 10;30(7):639-47. doi: 10.1038/nbt.2283.
10
TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection.T 细胞受体克隆型调节人类免疫缺陷病毒 1 感染中 HLA Ⅰ类分子的保护作用。
Nat Immunol. 2012 Jun 10;13(7):691-700. doi: 10.1038/ni.2342.